You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Authors

  • Ju Won Kim Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Hyo Jin Lee Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea PubMed articlesGoogle scholar articles
  • Ji Yoon Lee Department of Biomedical Informatics and Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Sook Ryun Park Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Yu Jung Kim Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea PubMed articlesGoogle scholar articles
  • In Gyu Hwang Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine and Graduate School of Medicine, Dongjak-gu, Republic of Korea PubMed articlesGoogle scholar articles
  • Woo Kyun Bae Division of Hemato-Oncology, Department of Internal Medicine, Chonnam National University Medical School & Hwasun Hospital, Hwasun, Republic of Korea PubMed articlesGoogle scholar articles
  • Jae Ho Byun Division of Oncology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Jung Sun Kim Division of Hemato-Oncology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea PubMed articlesGoogle scholar articles
  • Eun Joo Kang Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Jeeyun Lee Division of Hemato-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea PubMed articlesGoogle scholar articles
  • Sang Joon Shin Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun-gu, Republic of Korea PubMed articlesGoogle scholar articles
  • Won Jin Chang Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Eun-Ok Kim Medical Science Research Center, College of Medicine, Korea University, Seongbuk-gu, Republic of Korea PubMed articlesGoogle scholar articles
  • Jason K Sa Department of Biomedical Informatics and Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Kyong Hwa Park Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea PubMed articlesGoogle scholar articles

Citation

Kim JW, Lee HJ, Lee JY, et al
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Journal for ImmunoTherapy of Cancer 2024;12:e008638. doi: 10.1136/jitc-2023-008638
Online issue publication 
March 13, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.